Summary
208.07 1.26(0.61%)07/05/2024
IQVIA Holdings Inc (IQV)
IQVIA Holdings Inc (IQV)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.61 | -1.42 | -4.95 | -13.82 | -5.65 | -5.76 | 29.32 | 394.11 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 208.07 | |
| Open | 207.42 | |
| High | 208.50 | |
| Low | 205.16 | |
| Volume | 631,075 | |
| Change | 1.26 | |
| Change % | 0.61 | |
| Avg Volume (20 Days) | 978,790 | |
| Volume/Avg Volume (20 Days) Ratio | 0.64 | |
| 52 Week Range | 167.42 - 261.73 | |
| Price vs 52 Week High | -20.50% | |
| Price vs 52 Week Low | 24.28% | |
| Range | 0.31 | |
| Gap Up/Down | -1.17 | |
Fundamentals | ||
| Market Capitalization (Mln) | 37,916 | |
| EBIDTA | 2,342,000,128 | |
| PE Ratio | 66.8491 | |
| PEG Ratio | 1.0379 | |
| WallStreet Target Price | 300.22 | |
| Book Value | 30.5020 | |
| Earnings Per Share | 3.9290 | |
| EPS Estimate Current Quarter | 2.1200 | |
| EPS Estimate Next Quarter | 2.3800 | |
| EPS Estimate Current Year | 8.9100 | |
| EPS Estimate Next Year | 10.1400 | |
| Diluted EPS (TTM) | 3.9290 | |
| Revenues | ||
| Profit Marging | 0.0567 | |
| Operating Marging (TTM) | 0.0933 | |
| Return on asset (TTM) | 0.0330 | |
| Return on equity (TTM) | 0.1312 | |
| Revenue TTM | 13,536,000,000 | |
| Revenue per share TTM | 70.7030 | |
| Quarterly Revenue Growth (YOY) | 0.2170 | |
| Quarterly Earnings Growth (YOY) | 1.5770 | |
| Gross Profit (TTM) | 3,859,000,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 66.8491 | |
| Forward PE | 26.8097 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 8.8595 | |
| Revenue Enterprise Value | 4.6220 | |
| EBITDA Enterprise Value | 23.3530 | |
| Shares | ||
| Shares Outstanding | 191,040,000 | |
| Shares Float | 189,656,375 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.71 | |
| Institutions (%) | 90.64 | |
07/01 09:05 EST - zacks.com
Clinical Development Expertise Aids IQVIA (IQV), Costs High
IQVIA (IQV) benefits from its healthcare-specific global IT infrastructure and domain expertise to expand and penetrate different markets.
Clinical Development Expertise Aids IQVIA (IQV), Costs High
IQVIA (IQV) benefits from its healthcare-specific global IT infrastructure and domain expertise to expand and penetrate different markets.
06/25 08:00 EST - businesswire.com
IQVIA's SmartSolve® eQMS Wins 2024 MedTech Breakthrough Award “Best Use of Artificial Intelligence in Healthcare”
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the IQVIA SmartSolve Enterprise Quality Management System (eQMS) platform has been selected as the winner of the “Best Use of Artificial Intelligence in Healthcare" award in the 8th Annual MedTech Breakthrough Awards. SmartSolve eQMS is part of IQVIA's suite of purpose-built s.
IQVIA's SmartSolve® eQMS Wins 2024 MedTech Breakthrough Award “Best Use of Artificial Intelligence in Healthcare”
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the IQVIA SmartSolve Enterprise Quality Management System (eQMS) platform has been selected as the winner of the “Best Use of Artificial Intelligence in Healthcare" award in the 8th Annual MedTech Breakthrough Awards. SmartSolve eQMS is part of IQVIA's suite of purpose-built s.
06/13 14:07 EST - zacks.com
IQVIA (IQV) Announces Launch of Trial Technology Platform
IQVIA's (IQV) One Home for Sites allows pharmaceutical companies and their software vendors to streamline clinical application management.
IQVIA (IQV) Announces Launch of Trial Technology Platform
IQVIA's (IQV) One Home for Sites allows pharmaceutical companies and their software vendors to streamline clinical application management.
06/12 08:00 EST - businesswire.com
IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV) today announced the launch of One Home for Sites™, a new technology platform that acts as a single sign-on and a single dashboard for the key systems and tasks a clinical research site needs to perform across all of the clinical trials it is conducting. Clinical research sites manage scores of usernames and passwords in dozens of software applications as they navigate through numerous tasks they must complete each day in conducting.
IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV) today announced the launch of One Home for Sites™, a new technology platform that acts as a single sign-on and a single dashboard for the key systems and tasks a clinical research site needs to perform across all of the clinical trials it is conducting. Clinical research sites manage scores of usernames and passwords in dozens of software applications as they navigate through numerous tasks they must complete each day in conducting.
06/10 08:00 EST - businesswire.com
IQVIA Institute: Innovative Therapies and Strong Pipeline to Combat Rise in Cancer Diagnoses
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--As cancer incidence continues to rise, it's being met by wider use of innovative therapies and a robust pipeline of new drugs, according to a new report from the IQVIA Institute for Human Data Science titled, “Global Oncology Trends 2024: Outlook to 2028.” “The global oncology ecosystem is operating near peak levels to address increasing challenges. New therapies for advanced cancers, including some of the most advanced novel science in the industr.
IQVIA Institute: Innovative Therapies and Strong Pipeline to Combat Rise in Cancer Diagnoses
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--As cancer incidence continues to rise, it's being met by wider use of innovative therapies and a robust pipeline of new drugs, according to a new report from the IQVIA Institute for Human Data Science titled, “Global Oncology Trends 2024: Outlook to 2028.” “The global oncology ecosystem is operating near peak levels to address increasing challenges. New therapies for advanced cancers, including some of the most advanced novel science in the industr.
06/06 14:32 EST - youtube.com
Final Trades: Amazon, Goldman Sachs, AbbVie and IQVIA Holdings
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Amazon, Goldman Sachs, AbbVie and IQVIA Holdings
The Investment Committee give you their top stocks to watch for the second half.
05/27 15:57 EST - seekingalpha.com
IQVIA: Long-Term Compounder Throwing Off Free Cash Flow
There have been numerous positive updates to IQVIA Holdings' fundamental economics since January 2023. It produced strong Q1 2024 earnings, with growth observed in all segments. Increasing returns from margin growth and capital productivity are driving exceptional free cash flow production.
IQVIA: Long-Term Compounder Throwing Off Free Cash Flow
There have been numerous positive updates to IQVIA Holdings' fundamental economics since January 2023. It produced strong Q1 2024 earnings, with growth observed in all segments. Increasing returns from margin growth and capital productivity are driving exceptional free cash flow production.
05/24 12:20 EST - zacks.com
Here's Why You Should Hold on to IQVIA (IQV) Stock for Now
IQVIA (IQV) benefits from a powerful healthcare-specific global IT infrastructure and a robust real-world solutions ecosystem. However, high operating expenses are a headwind.
Here's Why You Should Hold on to IQVIA (IQV) Stock for Now
IQVIA (IQV) benefits from a powerful healthcare-specific global IT infrastructure and a robust real-world solutions ecosystem. However, high operating expenses are a headwind.
05/14 08:00 EST - businesswire.com
U.S. Medicines Spending Grew in 2023 as Greater Access Offset COVID-19-related Decline, Says IQVIA Institute
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Overall spending in the U.S. market for medicines grew by 2.5% and reached $435Bn in 2023. Excluding the contribution from COVID-19 vaccines and therapeutics, spending grew at 9.9%, according to a new report from the IQVIATM Institute for Human Data Science, The Use of Medicines in the U.S. 2024: Usage and Spending Trends and Outlook to 2028. The drop in COVID-19 vaccines and therapeutics masks the significant growth in medicines that are bringing.
U.S. Medicines Spending Grew in 2023 as Greater Access Offset COVID-19-related Decline, Says IQVIA Institute
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Overall spending in the U.S. market for medicines grew by 2.5% and reached $435Bn in 2023. Excluding the contribution from COVID-19 vaccines and therapeutics, spending grew at 9.9%, according to a new report from the IQVIATM Institute for Human Data Science, The Use of Medicines in the U.S. 2024: Usage and Spending Trends and Outlook to 2028. The drop in COVID-19 vaccines and therapeutics masks the significant growth in medicines that are bringing.
05/09 16:15 EST - businesswire.com
IQVIA CFO Ron Bruehlman to Speak at the Bank of America Health Care Conference on May 14, 2024
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank of America Health Care Conference in Las Vegas on Tuesday, May 14, 2024 at 12:20 p.m. ET (9:20 a.m. local PT). A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About.
IQVIA CFO Ron Bruehlman to Speak at the Bank of America Health Care Conference on May 14, 2024
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank of America Health Care Conference in Las Vegas on Tuesday, May 14, 2024 at 12:20 p.m. ET (9:20 a.m. local PT). A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About.
05/03 10:46 EST - zacks.com
Here's Why IQVIA Holdings (IQV) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why IQVIA Holdings (IQV) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
05/02 12:51 EST - zacks.com
IQVIA (IQV) Surpasses Earnings & Revenue Estimates in Q1
IQVIA's (IQV) rise in segmental revenues results in y/y top-line growth in first-quarter 2024.
IQVIA (IQV) Surpasses Earnings & Revenue Estimates in Q1
IQVIA's (IQV) rise in segmental revenues results in y/y top-line growth in first-quarter 2024.
05/02 12:14 EST - reuters.com
IQVIA trims full-year revenue forecast on stronger dollar
Contract research firm IQVIA Holdings lowered its annual revenue forecast on Thursday due to a stronger dollar and reported a quarter-over-quarter fall in a closely-watched metric, sending shares down nearly 4%.
IQVIA trims full-year revenue forecast on stronger dollar
Contract research firm IQVIA Holdings lowered its annual revenue forecast on Thursday due to a stronger dollar and reported a quarter-over-quarter fall in a closely-watched metric, sending shares down nearly 4%.
05/02 09:11 EST - zacks.com
IQVIA Holdings (IQV) Tops Q1 Earnings and Revenue Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $2.47 per share. This compares to earnings of $2.45 per share a year ago.
IQVIA Holdings (IQV) Tops Q1 Earnings and Revenue Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $2.47 per share. This compares to earnings of $2.45 per share a year ago.
05/02 07:00 EST - businesswire.com
IQVIA Reports First-Quarter 2024 Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2024. First-Quarter 2024 Operating Results Revenue for the first quarter of $3,737 million increased 2.3 percent on a reported basis and 2.9 percent at constant currency, compared to the first quarter of 2023. Te.
IQVIA Reports First-Quarter 2024 Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2024. First-Quarter 2024 Operating Results Revenue for the first quarter of $3,737 million increased 2.3 percent on a reported basis and 2.9 percent at constant currency, compared to the first quarter of 2023. Te.
05/01 16:30 EST - investorplace.com
Analysts Are Pounding the Table on These 3 Stocks: April 2024
Sometimes a company's debut or the release of a new product can stir analysts into a frenzy. Other times, careful consideration of long-term trends and performance can drive improved public opinion of a company's prospects.
Analysts Are Pounding the Table on These 3 Stocks: April 2024
Sometimes a company's debut or the release of a new product can stir analysts into a frenzy. Other times, careful consideration of long-term trends and performance can drive improved public opinion of a company's prospects.
04/29 11:30 EST - zacks.com
IQVIA (IQV) to Report Q1 Earnings: What's in the Offing?
IQVIA Holdings' (IQV) first-quarter 2024 revenues are likely to have benefited from growth in the Technology and Analytics, and Research and Development segments.
IQVIA (IQV) to Report Q1 Earnings: What's in the Offing?
IQVIA Holdings' (IQV) first-quarter 2024 revenues are likely to have benefited from growth in the Technology and Analytics, and Research and Development segments.
04/29 10:22 EST - zacks.com
Countdown to IQVIA (IQV) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for IQVIA (IQV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
Countdown to IQVIA (IQV) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for IQVIA (IQV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
04/25 11:06 EST - zacks.com
IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/23 09:00 EST - businesswire.com
IQVIA Celebrates Wendy Stewart and Susan Barnes, Winners of Healthcare Businesswoman's Association Luminary and Rising Star Awards
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV) today announced that Wendy Stewart, president of Clinical Operations at IQVIA, and Susan Barnes, senior director of IQVIA Biotech Strategic Operations, have been honored with the Healthcare Businesswoman's Association Luminary and Rising Star Awards, respectively. Wendy earned the award for her remarkable contributions to the healthcare industry, including her efforts in leading the teams responsible for the record-breaking deliver.
IQVIA Celebrates Wendy Stewart and Susan Barnes, Winners of Healthcare Businesswoman's Association Luminary and Rising Star Awards
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV) today announced that Wendy Stewart, president of Clinical Operations at IQVIA, and Susan Barnes, senior director of IQVIA Biotech Strategic Operations, have been honored with the Healthcare Businesswoman's Association Luminary and Rising Star Awards, respectively. Wendy earned the award for her remarkable contributions to the healthcare industry, including her efforts in leading the teams responsible for the record-breaking deliver.